ReviewNature reviews. Cardiology2024
Iron deficiency and supplementation in heart failure.
Review in Nature reviews. Cardiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 32 citations in OpenAlex.
- Adjudication of Hospitalizations and Deaths in the IRONMAN Trial of Intravenous Iron for Heart Failure.Journal of the American College of Cardiology · 2024Trial
- Impact of Shexiang Baoxin Pill (MUSKARDIA) on Cardiovascular Outcomes by Baseline Hemoglobin Levels in 2,494 Patients with Chronic Stable Coronary Artery Disease: A Secondary Subgroup Analysis.Chinese journal of integrative medicine · 2026Article
- Established and emerging roles of lysosomal dysfunction in cardiac aging.Nature cardiovascular research · 2026Review
- Iron deficiency and iron supplementation in heart failure: a dynamic phenotype and a moving therapeutic target.ESC heart failure · 2026Article
- Iron Balance and Cardiovascular Health: The Double-Edged Role of Deficiency and Overload.Cardiovascular toxicology · 2026Review
- Article
- Red Cell Distribution Width Predicts Mortality in Critically Ill Patients with COPD and Atrial Fibrillation: A Retrospective Cohort Study.International journal of chronic obstructive pulmonary disease · 2026Article
- Harnessing the gut microbiome for precision therapeutics in heart failure.Frontiers in pharmacology · 2026Review
- Beyond Iron: The Roles of CD71 in the Pathophysiology of Cancer-A Comprehensive Review.Journal of clinical medicine · 2025Review
- Baseline serum ferritin predicts myocardial iron uptake following intravenous iron therapy - a hypothesis-generating study.European journal of heart failure · 2025Article
- Oxidative stress activates YAP/TEAD1/NCOA4 axis to promote ferroptosis of endplate chondrocytes and aggravate intervertebral disc degeneration.Journal of orthopaedic translation · 2025Article
- Reassessment of the Current Iron Deficiency Definition in Pulmonary Hypertension.Pulmonary circulation · 2025Article
- Non-Anemic Iron Deficiency Predicts COPD Exacerbations and Hospitalizations: Results from a Prospective Cohort.Journal of clinical medicine · 2025Article
- Prevalence and prognostic value of different iron deficiency definitions in light chain cardiac amyloidosis patients.ESC heart failure · 2025Article
- Diagnosis and treatment of iron deficiency in chronic heart failure : Position statement of the heart failure working group of the Austrian Society of Cardiology.Wiener klinische Wochenschrift · 2025Article
- Targeting Inflammation and Iron Deficiency in Heart Failure: A Focus on Older Adults.Biomedicines · 2025Review
- Computational Prediction of Tissue Iron Dynamics in Iron Deficiency Anemia Following Intravenous Ferric Carboxymaltose Therapy.International journal of nanomedicine · 2025Article
- Hepcidin and Tissue-Specific Iron Regulatory Networks.Advances in experimental medicine and biology · 2025Review
- Iron Deficiency Anemia.Advances in experimental medicine and biology · 2025Review
- Diagnostics: Markers of Body Iron Status.Advances in experimental medicine and biology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Non-anaemic iron deficiency (NAID) is a strategic target in cardiovascular medicine because of its association with a range of adverse effects in various conditions. Endeavours to tackle NAID in heart failure have yielded mixed results, exposing knowledge gaps in how best to define 'iron deficiency' and the handling of iron therapies by the body. To address these gaps, we harness the latest understanding of the mechanisms of iron homeostasis outside the erythron and integrate clinical and preclinical lines of evidence. The emerging picture is that current definitions of iron deficiency do not assimilate the multiple influences at play in patients with heart failure and, consequently, fail to identify those with a truly unmet need for iron. Additionally, current iron supplementation therapies benefit only certain patients with heart failure, reflecting differences in the nature of the unmet need for iron and the modifying effects of anaemia and inflammation on the handling of iron therapies by the body. Building on these insights, we identify untapped opportunities in the management of NAID, including the refinement of current approaches and the development of novel strategies. Lessons learned from NAID in cardiovascular disease could ultimately translate into benefits for patients with other chronic conditions such as chronic kidney disease, chronic obstructive pulmonary disease and cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.